SER
Serina Therapeutics, Inc.
$1.75
-3.31%
2026-05-08
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Key Fundamentals
Forward P/E
-1.72
EPS (TTM)
$-1.91
ROE
-8159.2%
Profit Margin
0.0%
Debt/Equity
212.42
Beta
0.04
Market Cap
$27.0M
Avg Volume (10D)
46K
Recent Breakout Signals
No recent breakout signals detected for SER.
Recent Price Range (60 Days)
60D High
$3.29
60D Low
$1.22
Avg Volume
3.3M
Latest Close
$1.75
Get breakout alerts for SER
Sign up for Breakout Scanner to receive daily notifications when SER triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Serina Therapeutics, Inc. (SER) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors SER daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SER operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.